Published in

Springer Nature [academic journals on nature.com], Leukemia, 2(23), p. 402-404, 2008

DOI: 10.1038/leu.2008.185

Links

Tools

Export citation

Search in Google Scholar

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study

Journal article published in 2008 by J. K. Lamba, S. Pounds ORCID, X. Cao, J. R. Downing, D. Campana, R. C. Ribeiro, C.-H. Pui, J. E. Rubnitz ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody conjugated with calicheamicin (a cytotoxic antibiotic) that is used for the treatment of acute myeloid leukemia (AML). The relationship between the CD33 expression in leukemic cells and response to GO treatment has been controversial. We studied CD33 transcript and protein expression as well as polymorphisms in the CD33 gene in 22 uniformly treated pediatric AML patients and correlated the results with minimal residual disease (MRD) findings before and after GO. We found that a nonsynonymous coding change (Ala14Val) in CD33 was significantly associated with response to GO (P = .02) whereas CD33 transcript and protein expression were not (P > .2). The results suggest a novel mechanism of resistance to GO, one that may extend to other immunotoxins.